Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13228MR)

This product GTTS-WQ13228MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13228MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6083MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ11160MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ4182MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ11072MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ9588MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ3108MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ2022MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ6849MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW